Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419558 · ClinicalTrials.gov registry record · Phase 3
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3 study, sponsored by Kyntra Bio.
- Terminated
- Registry status
- Phase 3
- Development phase
- 372
- Enrollment target
NCT04419558 is a Phase 3 study that was terminated before completion, run by Kyntra Bio. The registered enrollment target is 372 participants.
The verdict
NCT04419558, a Phase 3 study, was terminated before completion, sponsored by Kyntra Bio.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 372 participants
- Enrollment target
Study Summary
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). There is a 48-week randomized treatment phase followed by an optional, open-label extension phase.
Interventions
- DRUG Placebo
- DRUG Pamrevlumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2023-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04419558
The ClinicalTrials.gov registry entry for NCT04419558 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04419558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04419558 about?
NCT04419558 is a clinical study titled "Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)". This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). There is a 48-week randomized treatment phase followed...
What is the current status of trial NCT04419558?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 372 participants. The study started on 2020-09-30. Estimated completion is 2023-09-04.
What interventions are being tested in trial NCT04419558?
The interventions under investigation include: Placebo (DRUG), Pamrevlumab (DRUG).
Who is sponsoring clinical trial NCT04419558?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.